gastroparesis glp 1 agonist Diabetic Gastrointestinal effect and adverse effects

Whats Next for Compounded GLP-1 Drugs

Novo Nordisk is putting down up to US$362m to tap into Ascendis TransCon technology for treatments in metabolic and cardiovascular diseases

Alpha-Lipoic Acid (ALA) adds antioxidant and metabolic support, assisting the bodys ability to utilize glucose more efficiently and support cellular energy production.*

Glucagon-like-peptide-1 receptor agonists (GLP-1s) have transformed weight management and treatment of chronic disease

This systematic review evaluates the literature on the relationship between GLP-1 RA use and increased regurgitation and aspiration events to contextualize the existing, consensus-based guidelines put forth by the ASA in light of limited comparative evidence